Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 16(4): e0249116, 2021.
Article in English | MEDLINE | ID: mdl-33798206

ABSTRACT

The increase in life expectancy and the migration of individuals with Chagas disease (ChD) from rural to urban centers exposes them to the development of chronic-degenerative abnormalities that may increase the prevalence of metabolic syndrome (MetS). The present study aimed to identify the prevalence of MetS and its components in individuals with chronic ChD. This is a cross-sectional study with 361 patients of both sexes, aging >18 years, followed at a national reference center (Rio de Janeiro, Brazil). MetS diagnosis followed the International Diabetes Federation 2005 criteria. The association between the variables was determined through logistic regression models. The mean age was and 60.7±10.8 years. About half (56.2%) were female and the majority self-reported their race as mulatto (59.8%). The percentage of individuals with MetS was 40.4%. The variables independently associated with MetS were age (OR 1.06; 95%CI 1.04-1.09), high education levels (OR 0.36; 95%CI 0.17-0.79) and cardiac form with heart failure (OR 0.34; 95%CI 0.17-0.68). Therefore, a high prevalence of MetS was found in this Brazilian chronic ChD cohort. The identification of the associated factors can facilitate the development of effective approaches for preventing and managing MetS in ChD patients.


Subject(s)
Chagas Disease/complications , Metabolic Syndrome/epidemiology , Adult , Brazil , Chagas Disease/epidemiology , Female , Humans , Male , Middle Aged , Prevalence
2.
Trials ; 19(1): 507, 2018 Sep 19.
Article in English | MEDLINE | ID: mdl-30231899

ABSTRACT

Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanisms of death in Chagas heart disease. The impact of specific etiologic treatment on the prognosis of patients with chronic Chagas heart disease is very limited regardless of the presence or absence of heart failure. Patients with symptomatic Chagas heart disease present serum selenium (Se) levels lower than patients without Chagas heart disease. Moreover, Se supplementation in animal models showed promising results. The aim of this trial is to estimate the effect of Se treatment on prevention of heart disease progression in patients with Chagas cardiomyopathy. However, we had to introduce some protocol modifications in order to keep trial feasibility, as follows: the primary outcome was restricted to left ventricular ejection fraction as a continuous variable, excluding disease progression; the follow-up period was decreased from 5 years to 1 year, an adjustment that might increase the participation rate of our study; the superior age limit was increased from 65 to 75 years; and diabetes mellitus was no longer considered an exclusion criterion. All of these protocol modifications were extensively debated by the research team enrolled in the design, recruitment and conduction of the clinical trial to guarantee a high scientific quality. TRIAL REGISTRATION: Clinical Trials.gov, NCT00875173 . Registered on 20 October 2008.


Subject(s)
Chagas Cardiomyopathy/drug therapy , Dietary Supplements , Sodium Selenite/therapeutic use , Adolescent , Adult , Aged , Chagas Cardiomyopathy/diagnosis , Chagas Cardiomyopathy/parasitology , Chagas Cardiomyopathy/physiopathology , Chronic Disease , Dietary Supplements/adverse effects , Disease Progression , Double-Blind Method , Endpoint Determination , Female , Humans , Male , Middle Aged , Patient Selection , Randomized Controlled Trials as Topic , Sodium Selenite/adverse effects , Stroke Volume/drug effects , Time Factors , Treatment Outcome , Ventricular Function, Left/drug effects , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...